Term
|
Definition
| 200 mg elemental, 325 mg so4 tid |
|
|
Term
|
Definition
| Sulfate, gluconate, fumarate or polysaccharide |
|
|
Term
|
Definition
| On empty stomach, acidic environment but may worsen GI side effects |
|
|
Term
|
Definition
| Hgb will increase 2weeks after therapy initiation and may normalize after 2-4 weeks |
|
|
Term
| Avoid concomittant administration with iron |
|
Definition
| Antacids, calcium, H2 antagonists and PPIs |
|
|
Term
|
Definition
| Abdominal pain, nausea, heartburn, constipation, dark stools |
|
|
Term
| Drug interactions of iron |
|
Definition
| Fluoroquinolones, tetracycline, phenytoin *blocks absorption of these drugs |
|
|
Term
|
Definition
| Assessed after at least 3 months of supplementation |
|
|
Term
| Increase of Hgb 1g/dL per week |
|
Definition
|
|
Term
| IV administration of iron |
|
Definition
| If patients unable to tolerate oral or non-responsive to oral |
|
|
Term
|
Definition
| Dextran, sucrose, gluconate |
|
|
Term
|
Definition
| IM formulation, test dose needed |
|
|
Term
|
Definition
| Only FDA approved for use with EPO in patients with CKD, costly, lower risk of anaphylaxis |
|
|
Term
| Test dose of iron dextrose |
|
Definition
| 0.5 mL (25mg) over 30sec followed by monitoring for S/Sx of anaphylaxis |
|
|
Term
|
Definition
|
|
Term
|
Definition
| 1mg/day po but may need up to 5mg in some cases of malabsorption |
|
|
Term
|
Definition
| Epoetin-alpha (Epogen, procrit), darbepoetin-alpha (Arnesp) |
|
|
Term
|
Definition
| Death, cardiovascular events, stroke, HTN |
|
|
Term
| Cancer patients caution with epo |
|
Definition
| Breast cancer, non-small cell lung cancer, head and neck cancer, lymphoid and cervical cancer |
|
|
Term
|
Definition
| Decreases incidence of pain, acute chest syndrome, and need for blood transfusion |
|
|
Term
|
Definition
| Myelosuppressive, acute leukemia, chronic opportunistic infections |
|
|
